Intercure vs Kamada
INCR and KMDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INCR and KMDA compare
Kamada grew revenue faster over the last twelve months (13.2% versus 13.1% for Intercure).
Kamada scores higher on the StockData Score (5 against 3 for Intercure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INCR | KMDA |
|---|---|---|
| Size and price | ||
| Share price | $3.98 | $8.09 |
| Change, 1 year | −43.5% | 11.1% |
| Change, 5 years | −89.9% | 44.5% |
| Beta (5Y) | 0.90 | 0.76 |
| Employees | – | 393 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 0 | 3 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 13.1% | 13.2% (better) |
| Revenue growth, 5Y average | 33.0% (better) | 6.3% |
| EPS growth, 5Y average | – | −1.6% |
| Profitability | ||
| Gross margin | 12.3% | 40.8% (better) |
| Operating margin | −10.1% | 14.5% (better) |
| Net margin | −13.2% | – |
| FCF margin | 4.9% | – |
| Return on equity | −9.0% | – |
| Return on invested capital | −4.0% | – |
| Financial health | ||
| Debt / equity | 0.49 | – |
| Net debt / EBITDA | – | −0.54 |
| Interest coverage | – | 26.8× |
| Current ratio | – | 4.06 |
| Piotroski F-score | 5 | – |
| Ownership | ||
| Held by institutions | 0.22% | 8.6% |
| Held by insiders | 30.8% | 45.3% |
| Insider net buying, 12 months | – | −$1.7M |
| Short interest, % of float | – | 0.53% |
Go deeper
- INCR stock overview
- INCR income statement
- INCR valuation and score
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.